In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis. - Wikidata - awgldk - TriplyDB

In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.

In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.

http://www.wikidata.org/entity/Q35089820

about

AAV-mediated liver-specific MPV17 expression restores mtDNA levels and prevents diet-induced liver failure Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders Mitochondrial disorders in children: toward development of small-molecule treatment strategies Mitochondrial cytochrome c oxidase deficiency Dysregulated metabolism contributes to oncogenesis Mitochondrial targets for pharmacological intervention in human disease Mitochondrial biogenesis through activation of nuclear signaling proteins PGC-1α, mitochondrial dysfunction, and Huntington's disease International Paediatric Mitochondrial Disease Scale Toward a therapy for mitochondrial disease Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice Functional analysis of missense mutations of OAT, causing gyrate atrophy of choroid and retina Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient Fibroblasts Screening for active small molecules in mitochondrial complex I deficient patient's fibroblasts, reveals AICAR as the most beneficial compound Primary respiratory chain disease causes tissue-specific dysregulation of the global transcriptome and nutrient-sensing signaling network Nitrite activates AMP kinase to stimulate mitochondrial biogenesis independent of soluble guanylate cyclase Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis Mitochondria: in sickness and in health GLTSCR2/PICT1 links mitochondrial stress and Myc signaling.Metabolite profiles reveal energy failure and impaired beta-oxidation in liver of mice with complex III deficiency due to a BCS1L mutation.β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors.NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease.A method to identify and validate mitochondrial modulators using mammalian cells and the worm C. elegans.The role of PGC-1 coactivators in aging skeletal muscle and heart.Therapies in inborn errors of oxidative metabolism.The optic nerve: a "mito-window" on mitochondrial neurodegeneration Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3 Long-term bezafibrate treatment improves skin and spleen phenotypes of the mtDNA mutator mouse.Mitochondrial dysfunction and lipid accumulation in the human diaphragm during mechanical ventilation.Mitochondrial Diseases Part I: mouse models of OXPHOS deficiencies caused by defects in respiratory complex subunits or assembly factors.Opa1 overexpression ameliorates the phenotype of two mitochondrial disease mouse models.Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease Transcriptome analysis of complex I-deficient patients reveals distinct expression programs for subunits and assembly factors of the oxidative phosphorylation system.Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies.The Arabidopsis KINβγ Subunit of the SnRK1 Complex Regulates Pollen Hydration on the Stigma by Mediating the Level of Reactive Oxygen Species in Pollen.Mitochondria: the next (neurode)generation Copper and bezafibrate cooperate to rescue cytochrome c oxidase deficiency in cells of patients with SCO2 mutations.Exploring the therapeutic space around NAD+.AFG3L2 supports mitochondrial protein synthesis and Purkinje cell survival.Tissue-specific implications of mitochondrial alterations in aging.

P2860

Q24622009-0D3E51A6-AB34-491E-A2F3-7226C5897341 Q26741300-9E87C723-2178-4500-893E-CE5B52E013D7 Q26767327-0B55ACFB-6AF7-474E-8322-6B4428BB32B8 Q26769015-F84CCC4B-F106-4720-9A74-7EF5189F2C20 Q26784630-2C82535B-248E-41B0-BB4B-19C172899557 Q26824514-86E16244-ADAE-4F03-82F4-714E249883D0 Q26991546-E5400822-6FEF-4A47-BAE1-DF957C54E34C Q27001671-A9A14167-5AF6-4CC3-A5C3-6862FD4FBCE9 Q27317267-FEBB4EC0-9200-4FF9-A14E-669E0D437358 Q28080024-B67E49FF-CFAA-48DC-9BAD-D3205F360495 Q28273620-0CD998B3-C508-47EB-AA79-D7E612CB84C1 Q28277356-23281DA0-4D30-41F2-A80F-8244E357D9AA Q28392510-A0E3ECE6-EAF1-4A5B-AAE5-30329FFE5336 Q28477645-B66D1C83-0F22-4C10-84EF-5F52577AA72D Q28534824-EA65790C-DEAC-4221-9290-914CE9A56896 Q28579907-051E6EDB-5FA2-4BE3-B0A4-DE79E112AECB Q29248145-66519A83-5623-45F2-BBA9-4778DC166AEF Q29614825-1217A875-E6EC-445F-A2C4-AEF01A2B338B Q29871472-A5113532-31C9-434A-8B17-666A34816206 Q31076216-5DF70DBD-AFAB-46AB-923C-04E75091746D Q33596037-DEB1C310-2843-4F0C-B0A2-B66A18061483 Q33735567-EDF8804B-9969-43C7-AFE0-DB4C01DC2887 Q33749557-84B8180A-216E-4CC9-9E9A-5A508925DA5D Q33840188-05162893-EF1C-4E0D-81B1-E96C73F856A4 Q34055267-DC170416-C83C-44C4-9937-51BC8BBACED2 Q34298350-EAC4F113-6539-4F81-A706-E447CBD769F4 Q34372265-08C95056-C22F-4B83-ACDE-D8127A204541 Q34409844-19D924E4-A569-45CB-B831-A77A1B24740A Q34424860-BD24BE7A-C727-4D72-9FFB-79D45F5F7347 Q35190973-3F7E53FC-3547-4DA9-82BE-11D6DC746B35 Q35689631-206A8E0D-9C2E-40D2-A65C-37420C646FD1 Q35750228-9786676B-70F0-4303-805D-CC1AB0E8CD85 Q35775042-6DDC7D1E-19DA-41E2-8553-68DD3D3C6144 Q35893619-3FD2A187-E4C4-4E12-A59E-824C16D81AF3 Q36089605-110C47B7-5E98-4ED1-B0F8-876E4685F665 Q36124905-F8A906A9-8A90-477A-A256-2F2280B004D6 Q36243954-3DB3F788-92C2-4678-82F0-41EDDF72F9BD Q36317201-5E1A41BF-6F6B-450C-8CE8-F3AAF5FA0D87 Q36357926-7362592B-4818-496B-99CC-8115679FAA3B Q36444696-4D1B85E8-FCD6-4F59-B085-022E8DB15098

P2860

In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.

http://www.wikidata.org/entity/Q35089820

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.

@ast

In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.

@en

type

label

In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.

@ast

In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.

@en

prefLabel

In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.

@ast

In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.

@en

P1433

Q35089820-EE9DD1CC-3113-4E47-80C0-F683EAFD6722

P1476

Q35089820-4A52BA05-D865-4D7F-9B0C-11B7E12C6AB9

P2093

Q35089820-33B9920B-3B43-4D5F-B9C3-D26648105D8B

Q35089820-4197704C-FD70-475A-9D13-4AB2ECEA1F5B

Q35089820-C394991E-E60F-416E-952F-A0CDECEC8D8E

Q35089820-D8055ADE-9C25-481F-8D25-E493906A0EAF

Q35089820-FDD14B4F-B4C9-4349-B518-8229DD477287

P2860

Q35089820-0226208B-5F05-46FF-ABA8-956BB93E83B2

Q35089820-08F2C8CA-5EEB-46FD-B680-F4C43317132D

Q35089820-0B91C989-E2C4-4F83-B65A-44D6E3F608D5

Q35089820-11358B0C-BAB1-4739-BE6A-7D4ED82F2348

Q35089820-2671D2A2-92D4-4621-99D6-1285DF2EA47C

Q35089820-3C3A9479-9099-4A5F-A05E-D1DC89361105

Q35089820-3C7A2682-4B58-44D7-AAD7-B25C8723BB05

Q35089820-40BC5332-AF4D-4E57-AACB-E39AAB91EE0D

Q35089820-49C38283-CB18-4651-8067-E1EA3660CDDF

Q35089820-4B8F050B-4A77-42C0-9664-F4D3EA6CE1C2

P304

Q35089820-2232BCFE-8093-4E18-8364-68B986C80347

P31

Q35089820-2CE28136-8E24-4B82-8C21-56B8AEFA410D

P356

Q35089820-19374A2A-4CF9-4DAF-BDDA-A192EC981E34

P433

Q35089820-D1E85294-7D0F-4464-884A-B8F5E6DBC2F4

P478

Q35089820-3FE36DA0-0197-4BCA-84DF-9FDD860625AE

P50

Q35089820-7118752A-3025-42B1-94BC-D90F88C56DDD

Q35089820-979F9D65-BE0E-44BA-A17A-EA2BE53FDD39

Q35089820-D0F87531-9207-43AC-B8D3-C1AF02D3B167

Q35089820-E846C2A8-B525-4E12-BF06-29E2D0791ED2

P577

Q35089820-EB31579E-5A12-4DFB-8C3E-7D369B0FE35B

P5875

Q35089820-201ECA0F-CEB0-455C-9B90-D779618EBDEF

P698

Q35089820-6EB928BE-944F-45B6-BD15-4ACCC03547CE

P932

Q35089820-CFA87E60-6EA2-491C-9AC3-6A2B575FAE5B

P356

J.CMET.2011.04.011

P1433

Cell Metabolism

P1476

In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.

@en

P2093

Carlo Viscomi

http://www.w3.org/2001/XMLSchema#string

Emanuela Bottani

http://www.w3.org/2001/XMLSchema#string

Eric A Schon

http://www.w3.org/2001/XMLSchema#string

Gabriele Civiletto

http://www.w3.org/2001/XMLSchema#string

Raffaele Cerutti

http://www.w3.org/2001/XMLSchema#string

P2860

Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene

Mutations in COX15 produce a defect in the mitochondrial heme biosynthetic pathway, causing early-onset fatal hypertrophic cardiomyopathy

PPAR delta: a dagger in the heart of the metabolic syndrome.

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis

AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity

Regulation of muscle fiber type and running endurance by PPARdelta

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha

Mitochondrial disorders

P304

80-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CMET.2011.04.011

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Zeviani

Costanza Lamperti

Maurizio Moggio

Gigliola Fagiolari

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51461835

http://www.w3.org/2001/XMLSchema#string

P698

21723506

http://www.w3.org/2001/XMLSchema#string

P932

3130927

http://www.w3.org/2001/XMLSchema#string